Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI Versus Placebo With FOLFIRI as Second-Line Therapy in Patients With Metastatic Colorectal Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Regorafenib (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- 11 Oct 2016 Primary endpoint (Progression Free Survival (PFS)) has been met.
- 11 Oct 2016 Results assessing efficacy and safey presented at the 41st European Society for Medical Oncology Congress
- 10 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.